Download PDF
Dtsch Med Wochenschr 2022; 147(21): 1383-1390
DOI: 10.1055/a-1825-4967
Dossier

Einsatz antifibrotischer Medikamente bei interstitiellen Lungenerkrankungen

Use of antifibrotic drugs in interstitial lung disease
Claus-Peter Kreutz
,
Wolfgang Gesierich
,
Jürgen Behr
,
Nikolaus Kneidinger
› Further Information
Also available at
    Permissions and Reprints

Interstitielle Lungenerkrankungen (ILD) führen oftmals zu einer progredienten Fibrosierung der Lunge und damit zu entsprechenden Funktionseinschränkungen. Bei der rasch fortschreitenden idiopathischen pulmonalen Fibrose (IPF) sind antifibrotische Medikamente bereits seit einigen Jahren in der Therapie etabliert. Der Beitrag bietet eine Übersicht über den Einsatz antifibrotischer Medikamente, sowohl bei der IPF als auch bei den speziellen non-IPF-ILDs.

Abstract

The interstitial lung diseases ILDs are a heterogeneous group of diseases that often lead to progressive fibrosis of the lungs with corresponding functional impairment. With nintedanib, a tyrosinkinase inhibitor and angiokinase inhibitor, as well as pirfenidone, which unfolds its effect among other things by inhibiting the transforming growth factor β, there are currently 2 approved antifibrotic drugs. In the rapidly progressing idiopathic pulmonary fibrosis IPF, the antifibrotic drugs nintedanib and pirfenidone have been established and approved in therapy for several years. The initiation of antifibrotic therapy should be carried out early after diagnosis by multidisciplinary discussion (MDD). In systemic scleroderma with lung involvement nintedanib should be used in the case of relevant fibrosis in addition to immunosuppressive therapy. Recently, nintedanib has also become a new option for the treatment of progressive fibrosing ILDs (PF-ILDs). This describes the course of various disease entities such as connective tissue disease associated ILDs (CTD-ILDs), fibrosing hypersensitivity pneumonitis or fibrosing courses of non-IPF idiopathic interstitial pneumonitis (non-IPF IIPs) that have a corresponding fibrose-related worsening of respiratory symptoms, a deterioration of lung-functioning parameters or a disease progression in CT. Although pirfenidone also shows positive signals for this group of patients in some selected studies, its use in PF-ILD is not yet recommended. In particular, gastrointestinal side effects can occur under therapy with antifibrotic drugs and require a long-term close interdisciplinary connection of patients.

Schlüsselwörter

interstitielle Lungenerkrankungen - antifibrotische Therapie - Nintedanib, Pirfenidon

Abstract

interstitial lung disease - antifibrotic therapy - nintedanib - pirfenidone


Publication History

Article published online:
24 October 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Wollin L, Wex E, Pautsch A. et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434-1445
    CrossrefPubMedSearch in Google Scholar
  • 2 Kwapiszewska G, Gungl A, Wilhelm J. et al. Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. Eur Respir J 2018; 52
    CrossrefPubMedSearch in Google Scholar
  • 3 Raghu G, Anstrom KJ, King TE. et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977
    CrossrefPubMedSearch in Google Scholar
  • 4 Oldham JM, Witt LJ, Adegunsoye A. et al. N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulm Med 2018; 18: 30
    CrossrefPubMedSearch in Google Scholar
  • 5 Noble PW, Albera C, Bradford WZ. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769
    CrossrefPubMedSearch in Google Scholar
  • 6 King TE, Bradford WZ, Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092
    CrossrefPubMedSearch in Google Scholar
  • 7 Richeldi L, Du Bois RM, Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082
    CrossrefPubMedSearch in Google Scholar
  • 8 Behr J, Günther A, Bonella F. et al. S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017. Pneumologie 2017; 71: 460-474
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Albera C, Costabel U, Fagan EA. et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016; 48: 843-851
    CrossrefPubMedSearch in Google Scholar
  • 10 Collard HR, Richeldi L, Kim DS. et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J 2017; 49
    CrossrefPubMedSearch in Google Scholar
  • 11 Costabel U, Albera C, Lancaster LH. et al. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration 2017; 94: 408-415
    CrossrefPubMedSearch in Google Scholar
  • 12 Lancaster L, Albera C, Bradford WZ. et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res 2016; 3: e000105
    CrossrefPubMedSearch in Google Scholar
  • 13 Crestani B, Huggins JT, Kaye M. et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. The Lancet Respiratory Medicine 2019; 7: 60-68
    CrossrefPubMedSearch in Google Scholar
  • 14 Richeldi L, Kreuter M, Selman M. et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 2018; 73: 581-583
    CrossrefPubMedSearch in Google Scholar
  • 15 Kreuter M, Picker N, Schwarzkopf L. et al. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis. Respir Res 2022; 23: 62
    CrossrefPubMedSearch in Google Scholar
  • 16 Dempsey TM, Payne S, Sangaralingham L. et al. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc 2021; 18: 1121-1128
    CrossrefPubMedSearch in Google Scholar
  • 17 Vancheri C, Kreuter M, Richeldi L. et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med 2018; 197: 356-363
    CrossrefPubMedSearch in Google Scholar
  • 18 Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 2019; 20: 13
    CrossrefPubMedSearch in Google Scholar
  • 19 Prasse A, Bonella F, Müller-Ladner U. et al. Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung. Z Rheumatol 2020; 79: 294-303
    CrossrefPubMedSearch in Google Scholar
  • 20 Distler O, Highland KB, Gahlemann M. et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 2019; 380: 2518-2528
    CrossrefPubMedSearch in Google Scholar
  • 21 Acharya N, Sharma SK, Mishra D. et al. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int 2020; 40: 703-710
    CrossrefPubMedSearch in Google Scholar
  • 22 Flaherty KR, Wells AU, Cottin V. et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381: 1718-1727
    CrossrefPubMedSearch in Google Scholar
  • 23 Maher TM, Brown KK, Kreuter M. et al. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J 2022; 59
    CrossrefPubMedSearch in Google Scholar
  • 24 Wells AU, Flaherty KR, Brown KK. et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Resp Med 2020; 8: 453-460
    CrossrefPubMedSearch in Google Scholar
  • 25 Raghu G, Remy-Jardin M, Richeldi L. et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205: e18-e47
    CrossrefPubMedSearch in Google Scholar
  • 26 Maher TM, Corte TJ, Fischer A. et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine 2020; 8: 147-157
    CrossrefPubMedSearch in Google Scholar
  • 27 Behr J, Prasse A, Kreuter M. et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet Respiratory Medicine 2021; 9: 476-486
    CrossrefPubMedSearch in Google Scholar
  • 28 Wells AU. Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed. The Lancet Respiratory Medicine 2021; 9: 437-438
    CrossrefPubMedSearch in Google Scholar
  • 29 Ghazipura M, Mammen MJ, Bissell BD. et al. Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2022; 19 (06) 1030-1039
    CrossrefPubMedSearch in Google Scholar
  • 30 Bendstrup E, Wuyts W, Alfaro T. et al. Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potenzial Adverse Events. Respiration 2019; 97: 173-184
    CrossrefPubMedSearch in Google Scholar
  • 31 Rodríguez-Portal JA. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update. Drugs R D 2018; 18: 19-25
    CrossrefPubMedSearch in Google Scholar